Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Métodos Terapéuticos y Terapias MTCI
Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Hepatogastroenterology ; 58(105): 235-8, 2011.
Artículo en Inglés | MEDLINE | ID: mdl-21510321

RESUMEN

BACKGROUND/AIMS: Ideally, medications for the treatment of acid-related diseases should have a rapid onset of action to promote hemostasis and the resolution of symptoms. The aim of our study was to investigate the inhibitory effects on gastric acid secretion of a single oral administration of lafutidine alone or combined with peppermint oil. METHODOLOGY: Ten Helicobacter pylori-negative male subjects participated in this randomized, two-way crossover study. Intragastric pH was monitored continuously for 4 hours after a single oral administration of lafutidine (10 mg) or the administration of lafutidine (10 mg) with peppermint oil (0.64 mL). Each administration was separated by a 7-day washout period. RESULTS: No significant difference in the average pH was observed during the 4-hour period after the combined administration of lafutidine and peppermint oil and after the administration of lafutidine alone (median gastric pH: 5.09 versus 5.29; p = 0.3122). CONCLUSIONS: In H. pylori-negative healthy male subjects, an oral dose of lafutidine combined with peppermint oil did not increase the intragastric pH faster than lafutidine alone.


Asunto(s)
Acetamidas/administración & dosificación , Antiulcerosos/administración & dosificación , Determinación de la Acidez Gástrica , Piperidinas/administración & dosificación , Aceites de Plantas/administración & dosificación , Piridinas/administración & dosificación , Administración Oral , Adulto , Estudios Cruzados , Humanos , Concentración de Iones de Hidrógeno , Masculino , Mentha piperita , Estadísticas no Paramétricas
2.
J Hepatol ; 51(3): 548-56, 2009 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-19596472

RESUMEN

BACKGROUND/AIMS: Non-alcoholic fatty liver disease (NAFLD) is a hepatic manifestation of metabolic syndrome that is closely associated with multiple factors such as obesity, hyperlipidemia, type 2 diabetes mellitus and hypertension, making it difficult to treat NAFLD effectively using any monotherapy available to date. In this study, we propose a novel combination therapy for NAFLD comprising ezetimibe (EZ), a cholesterol absorption inhibitor, and acarbose (AC), an alpha-glucosidase inhibitor. METHODS: C57BL/6J mice were divided into five treatment groups as follows: basal diet (BD), high-fat diet (HFD) only, HFD with EZ (5mg/kg/day), HFD with AC (100mg/kg/day), and HFD with both EZ and AC for 24 weeks. RESULTS: Long-term combination therapy with EZ and AC significantly reduced steatosis, inflammation and fibrosis in the liver, compared with long-term monotherapy with either drug, in an HFD-induced NAFLD mouse model; the combination therapy also significantly increased the expression of microsomal triglyceride transfer protein (MTP) and peroxisome proliferators-activated receptor-alpha1 (PPAR-alpha1) in the liver, compared with either monotherapy, which may have led to the improvement in lipid metabolic disorder seen in this model. CONCLUSIONS: Combination therapy with EZ and AC for 24 weeks improved the histopathological findings in a mouse model of NAFLD.


Asunto(s)
Acarbosa/uso terapéutico , Anticolesterolemiantes/uso terapéutico , Azetidinas/uso terapéutico , Inhibidores Enzimáticos/uso terapéutico , Hígado Graso/tratamiento farmacológico , Acarbosa/farmacología , Animales , Anticolesterolemiantes/farmacología , Azetidinas/farmacología , Proteínas Portadoras/metabolismo , Colesterol/metabolismo , Grasas de la Dieta/efectos adversos , Modelos Animales de Enfermedad , Quimioterapia Combinada , Inhibidores Enzimáticos/farmacología , Ezetimiba , Hígado Graso/etiología , Hígado Graso/metabolismo , Hígado/efectos de los fármacos , Hígado/metabolismo , Hígado/patología , Cirrosis Hepática/tratamiento farmacológico , Cirrosis Hepática/metabolismo , Cirrosis Hepática/patología , Masculino , Ratones , Ratones Endogámicos C57BL , PPAR alfa/metabolismo , Receptores de LDL/metabolismo , Proteína 1 de Unión a los Elementos Reguladores de Esteroles/metabolismo , Triglicéridos/metabolismo
3.
Hepatogastroenterology ; 56(91-92): 918-20, 2009.
Artículo en Inglés | MEDLINE | ID: mdl-19621729

RESUMEN

BACKGROUND/AIMS: Coffee is one of the most popular beverages worldwide, however, few studies have examined the effects of coffee on the gastrointestinal system. The aim of this study was to determine whether there was a correlation between coffee intake and gastric emptying using a novel non-invasive technique for measuring gastric emptying with a continuous real time 13C breath test (BreathID system: Oridion, Israel). METHODOLOGY: Six healthy male volunteers participated in this randomized, two-way crossover study. The subjects were randomly assigned to receive a test meal (200 kcal per 200 mL) plus postprandial 190 mL black coffee or the test meal alone after fasting overnight. A 13C-acetic acid breath test was continuously performed using the BreathID system, which monitors gastric emptying, for 4 hours after the administration of the test meal. Using Oridion Research Software (beta version), the time for emptying of 50% of the labeled meals (T 1/2) and the analog to the scintigraphy lag time for 10% emptying of the labeled meal (T lag) were calculated. The parameters between two occasions were compared using the Wilcoxon signed-rank test. RESULTS: After coffee intake the T 1/2 and T lag constant were significantly decreased. CONCLUSIONS: The decrease in the T 1/2 and T lag suggests the acceleration of gastric emptying. This study showed that postprandial coffee intake enhances gastric emptying, suggesting the potential use of coffee in clinical settings for patients with functional gastrointestinal disorders.


Asunto(s)
Café , Vaciamiento Gástrico/efectos de los fármacos , Periodo Posprandial/fisiología , Pruebas Respiratorias , Estudios Cruzados , Ingestión de Líquidos , Humanos , Masculino , Valores de Referencia , Adulto Joven
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA